Pembrolizumab Shows Overall Survival Benefit at 3 Years in Advanced NSCLC
KEYNOTE-024 shows first-line pembrolizumab has long-term overall survival benefit in patients with advanced non-small cell lung cancer and PD-L1–expressing disease.
Lung Cancer
Long-Term OS Benefit for Nivolumab Vs Docetaxel in Previously Treated Patients With Advanced NSCLC: A Pooled Analysis
Although historically, the 5-year OS rate for patients with advanced NSCLC treated with chemotherapy is less than 5%, patients treated with nivolumab had a 5-year OS of 13.4%.
Rationale for Mesothelin-Directed CAR-T Therapy in Metastatic, KRAS-Mutant Lung Adenocarcinoma
Preclinical studies performed in cell line and mouse models of lung adenocarcinoma showed that mesothelin-directed CAR-T was effective and not associated with toxicity.
No OS Benefit for Addition of Atezolizumab to Nab-Paclitaxel and Carboplatin in Squamous NSCLC Unselected for Tumor PD-L1 Expression
OS was significantly higher in the subgroup of patients with high tumor expression of PD-L1 who received atezolizumab plus chemotherapy compared with chemotherapy alone.
Immunotherapy-Induced Hyperprogressive Disease Is Real
Disease progression was accelerated in nearly 21% of NSCLC patients who received immunotherapy during the trial, suggesting this treatment may be detrimental for some.
OS Benefit Seen With Addition of Durvalumab to Standard Chemotherapy in Extensive-Stage SCLC
The incidences of grade 3/4 AEs were high but similar in both study arms, although the rate of hematologic AEs was higher in the chemotherapy alone arm.
Quality of Life Is Underreported Across Phase 3 Lung Cancer Trials
QoL measures either remained unpublished — despite being studied — or were not reported at all.
Insights From the Largest Global Precision Medicine Trial in NSCLC: The National Lung Matrix Trial
Continued molecular stratification in lung cancer appears imminent, and many of the patients in these genetic subgroups may benefit from the use of targeted therapies.
Promising Efficacy and Safety for Selpercatinib, a RET Fusion Inhibitor, in Advanced NSCLC
Fewer than 2% of the people in the LIBRETTO-001 study discontinued treatment with selpercatinib due to treatment-related adverse events.
Early Evidence Supporting KRAS G12C as a Druggable Target: High Response Rate for AMG 510 in Advanced NSCLC
Of the 23 patients with NSCLC who were evaluable for efficacy, the overall response rate was 48%, with a disease control rate of 96%.
Next post in IASLC/WCLC 2019
